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The G4C2-repeat expansion in C9orf72 is a common cause of frontotemporal lobar degeneration (FTLD) and
amyotrophic lateral sclerosis (ALS).C9orf72 transcription is reduced in expansion carriers implicating haploin-
sufficiency as one of the disease mechanisms. Indeed, our recent ALS study revealed that the expansion was
associatedwithhypermethylationof theCpG-island (5′of the repeat) inDNAsamplesobtained fromdifferent tis-
sues (blood, brain and spinal cord). However, the link between FTLD and methylation of the CpG-island is un-
known. Hence, we investigated the methylation profile of the same CpG-island by bisulfite sequencing of DNA
obtained from blood of 34 FTLD expansion carriers, 166 FTLD non-carriers and 103 controls. Methylation
levelwassignificantlyhigher inFTLDexpansioncarriers thannon-carriers (P 5 7.8E213).Our resultswerecon-
firmed by two methods (HhaI-assay and sequencing of cloned bisulfite PCR products). Hypermethylation oc-
curred only in carriers of an allele with >50 repeats, and was not detected in non-carriers or individuals with
an intermediate allele (22–43 repeats). As expected, the position/number of methylated CpGs was concordant
between the sense and anti-sense DNA strand, suggesting that it is a stable epigenetic modification. Analysis
of the combined ALS and FTLD datasets (82 expansion carriers) revealed that the degree of methylation of the
entire CpG-island or contribution of specific CpGs (n 5 26) is similar in both syndromes, with a trend towards
a higher proportion of ALS patients with a high methylation level (P 5 0.09). In conclusion, we demonstrated
that hypermethylation of the CpG-island 5′of the G4C2-repeat is expansion-specific, but not syndrome-specific
(ALS versus FTLD).
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INTRODUCTION
Amyotrophic lateral sclerosis [ALS (MIM 612069)] and fronto-
temporal lobar degeneration [FTLD (MIM 600274)] are two
ends of a clinico-pathological spectrum of overlapping neurode-
generative syndromes (1–4).
FTLD is caused by degeneration of the frontal/temporal lobes
of the cerebral cortex leading to behavioral and/or language dis-
ruptions (5); while ALS is caused by degeneration of upper
motor neurons in the cerebral cortex as well as lower motor
neurons of the brainstem and anterior horn of the spinal cord
resulting in paralysis (6). The co-occurrence of both syndromes
can be observed within the same family and individual patients
(4). Yet, there are many patients presenting with either pure
FTLD or pure ALS even among individuals with identical patho-
logical mutations (7). Such a phenotypic split is unexplained
and could be the result of environmental, genetic or epigenetic
modifications. The latter is investigated in the current study.
ALS and FTLD are genetically complex and might be
explained by mutations in several often overlapping genes (7).
Discovery of the hexanucleotide G4C2-repeat expansion (up to
several thousand repeats) within the non-coding region of
C9orf72 (MIM 614260) as the most common known cause of
both ALS and FTLD provides additional evidence of shared
pathological mechanisms (8–10). It is critical to understand
whether expansion withdifferent sizeshave the samepathological
consequence, however even the lower limit of repeat number for
pathological expansions has not been determined. Most C9orf72
studies are using a 30-repeat cutoff, which likely will be corrected
based on the cumulative evidence of numerous reports including
the current study. It is important to uncover functionally relevant
markers (e.g. epigenetic modifications investigated here) that can
be exploited to circumvent the technical difficulty in measuring
the length of the expansion by Southern blot.
Proposed C9orf72-related mechanisms include the formation
of toxic RNA foci consisting of transcribed repeat sequence (8);
the generation of aggregating dipeptide-repeat proteins due to
non-ATG translation of the repeat (11,12); and haploinsuffi-
ciency of C9orf72 (8), which might affect the Rab-dependent
vesicular trafficking process (13,14). It is also likely that all
three mechanisms contribute to the diverse phenotypes to a
variable extent.
Importantly, the G4C2-repeat is mapped directly or proximal
to the C9orf72 promoter (depending on the transcript); adjacent
to two cytosine-phosphate-guanine (CpG) islands and enriched
in CpGs itself (15). Hypermethylation of CpG-islands at the pro-
moter region could lead to gene expression silencing reported for
other repeat expansion diseases such as Friedreich’s ataxia
(MIM 229300) (16–18), Fragile X syndrome (MIM 300624)
(19–21) and myotonic dystrophy (MIM 160900) (22–24).
Indeed, the G4C2-repeat expansion lead to an 50% reduction
of C9orf72 transcripts in brain or blood of mutation carriers
(8,10,15). In agreement with the pathological impact of
reduced C9orf72 expression, down-regulation of the zebrafish
C9orf72 orthologue led to altered motor neuron axon morph-
ology and locomotor deficits rescued upon overexpression of
human C9orf72 (25). Similarly, a null mutation of the Caenor-
habditis elegans C9orf72 orthologue caused age-dependent
motility defects leading to paralysis and the specific degener-
ation of GABAergic motor neurons (26).
Our recent ALS study further supports the loss-of-function
model to be one of the disease mechanisms. At the CpG-island
5′ (but not 3′) of the G4C2-repeat, methylation level was signifi-
cantly higher in ALS expansion carriers than in non-carriers
(ALS and controls) (15). In addition, qRT-PCR results supported
that hypermethylation may underlie the reduced C9orf72 ex-
pression, since carriers of larger expansions (.50 repeats)
showed a high methylation level together with a reduction in
C9orf72 expression, while individuals carrying unmethylated
wild-type or intermediate alleles had a normal level of
expression (15).
It is critical to know whether DNA hypermethylation also
occurs in FTLD expansion carriers and whether it is essential
in modifying the disease phenotype (ALS versus FTLD).
Hence, we conducted a methylation analysis of the 5′ CpG-island
in an FTLD dataset, and compared the methylation profile
between FTLD and ALS expansion carriers. We report that
hypermethylation of the CpG-island occurs exclusively in
expansion carriers at a rate similar for both syndromes.
RESULTS
Analysis of FTLD dataset
FTLD patients (n ¼ 200) and origin-matched controls (n ¼ 103)
were genotyped for theC9orf72 repeat region (Table 1). None of
the controls had the expansion (≤20 repeats). Based on the elec-
tropherogram with saw-tooth peaks (Supplementary Material,
Fig. S1), 34 FTLD expansion carriers were detected (including
a case with a 31-repeat allele). In addition, we identified four
carriers of an intermediate allele (22, 23, 28 and 30 repeats).
Compared with FTLD non-carriers, FTLD expansion carriers
have a significantly younger age of onset (P ¼ 0.00005), a
higher percentage of cases with familial history (P ¼ 0.004)
and an FTLD/ALS diagnosis (P ¼ 0.008), all of which are
known associations (10,27).
All samples were studied by direct bisulfite sequencing (a rep-
resentative chromatogram is shown in Fig. 1). As in the previous
ALS study (15), the total number of methylated CpGs obtained for
each sample was used to categorize samples to three methylation
levels:0 (nomethylation);1–3(lowmethylation);and4–26(high
methylation). Among the 34 expansion carriers, 56% (n¼ 19)
were in the low or no methylation category and 21% (n¼ 7)
were in the high methylation category. In contrast, no highly
methylated samples were found in the 269 non-carriers and only
6% of them (n¼ 16) were methylated at a low level (Table 2).
The methylation level was significantly higher in FTLD expan-
sion carriers versus FTLD non-carriers (P¼ 7.8E213); and in
FTLD expansion carriers versus controls (P¼ 8.3E29), while
no difference was found between the two non-expansion groups
(FTLD versus controls, P ¼ 0.128). Similar results were obtained
when comparing the high methylation group to the combined
no/low methylation group (FTLD expansion carriers versus
FTLD non-carriers, P¼ 2.4E26; FTLD expansion carriers
versus controls P¼ 3.5E25).
The defined methylation categories were confirmed by
sequencing of cloned bisulfite PCR (BSP) products from six ran-
domly selected expansion carriers (two samples per methylation
category). A representative bisulfite sequence chromatogram
is shown in Supplementary Material, Fig. S2A. Of note, all
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investigated carriers are heterozygous for the expansion; there-
fore, the highest methylation percentage should be up to
50%, if only the expanded allele is methylated. Indeed, the per-
centage of methylation was highest in the high methylation cat-
egory (18–51%) versus the low (0.4–4%) or no (0.4–0.8%)
methylation categories (Supplementary Material, Fig. S2B).
The direct bisulfite sequencing results were further con-
firmed by the methylation sensitive HhaI-assay developed pre-
viously (15). The observed methylation (OM) ratio was
significantly higher in the group of 34 FTLD expansion
carriers (mean+ SD ¼ 0.46+ 0.40) versus 166 FTLD non-
carriers (mean+SD¼ 0.26+0.21, Mann–Whitney U test
P ¼ 0.005) or versus 103 controls (mean+SD ¼ 0.15+0.13,
Mann–Whitney U test P ¼ 9.7E28). A representative gel
image of 8 samples from each group is shown in Supplementary
Material, Fig. S3. A scatter plot of the OM ratio against the
number of methylated CpGs revealed a significant correlation
between the two assays (P, 0.0001) (Supplementary Material,
Fig. S3).
Regarding the individual CpG-sites, we observed that any of
the 26 evaluated CpGs could be methylated in expansion carriers
(Fig. 2). No correlation was found in the expansion carriers
between the number of methylated CpGs and wild-type allele
(2–11 repeats in our dataset): Spearman’s correlation
coefficient ¼ 20.068, P ¼ 0.708. Of note, samples from all 5
FTLD patients carrying an intermediate allele (22–31 repeats)
Table 1. Clinical characteristics and C9orf72 repeat genotypes for the investigated dataset
Characteristic of the dataset FTLD patients Controls
Expansion carriers Non-expansion carriers Non-expansion carriers
Total number 34 166 103
Age of sample collection (+SD) 63.0+8.3 70.5+8.1 73.2+6.3
Age at onset (+SD) 58.6+8.7 66.2+8.8 –
P-valuea (FTLD carrier versus non-carrier) 0.00005∗ – –
Female (no/frequency) 18 (0.53) 84 (0.51) 57 (0.55)
P-valueb (FTLD carrier versus non-carrier) 0.804 – –
Family history (no/frequency) 22 (0.65) 63 (0.38) –
P-valueb (FTLD carrier versus non-carrier) 0.004∗ – –
Diagnosis (no/frequency) FTLD 29 (0.85) 162 (0.98) –
FTLD/ALS 5 (0.15) 4 (0.02) –
P-valueb (FTLD carrier versus non-carrier) 0.008∗ – –
C9orf72 repeat number (range) Small allele 2–11 2–12 2–9
Big allele 31, .50 repeat expansion 2–30 2–20
aThe independent samples t-test was used.
bTwo-sided Pearson x2 test or Fisher’s exact test was used (when expected value is ,5).
∗P , 0.05.
Figure 1.Bisulfite sequencing result. Representative chromatograms of a sequence containing seven CpG-sites (indicated by black squares at the top of the sequence
diagram) are shown for an FTLD expansion carrier, an FTLD non-expansion carrier and a control. All non-CpG cytosine (indicated by blue squares) were successfully
converted to thymine.
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were completely unmethylated. In expansion carriers, methyla-
tion level did not correlate with age of onset of FTLD (44–74
years old; Spearman’s correlation coefficient ¼ 20.006, P ¼
0.975), age at time of examination (46–76 years old; Spearman’s
correlation coefficient ¼ 0.002, P ¼ 0.991), or gender (Fisher
exact test P ¼ 0.132). Among the seven expansion carriers
who had high methylation levels, five were pure FTLD patients
and two were ALS/FTLD patients. Of note, all five FTLD
patients had positive family history; however the association
between degree of methylation and FTLD family history did
not reach statistical significance likely due to the small sample
size (Supplementary Material, Table S1).
Combined analysis of FTLD and ALS datasets
To address the question whether DNA methylation plays a role in
modifying disease phenotypes (ALS versus FTLD), we con-
ducted a combined analysis of the FTLD dataset, our published
ALS dataset (15) and 11 recently identified ALS expansion
carriers. In total we analyzed 82 expansion carriers (42 ALS,
29 FTLD and 11 ALS/FTLD patients). A comparison of the
three disease categories revealed a similar distribution of methy-
lation level (P . 0.05), suggesting that it is not a major modify-
ing factor for disease phenotype (Supplementary Material,
Table S2).
In addition, no significant difference between ALS and FTLD
was found in methylation frequency of individual CpGs,
although the methylation frequency for many CpGs was margin-
ally higher in ALS versus FTLD (Supplementary Material,
Fig. S4). A tendency for more highly methylated samples
was observed in ALS (36% cases) versus FTLD (17% cases)
(P ¼ 0.09; Supplementary Material, Table S2). A similar
result was obtained when comparing the FTLD expansion car-
riers to the ALS and ALS/FTLD carriers combined (P ¼ 0.08).
Methylation analysis of the CpG-island on anti-sense
DNA strand
All of the methylation data above was obtained from the sense
strand encoding C9orf72. This is of note since the bisulfite
sequencing assay can only obtain information from a single
strand (after bisulfite conversion the DNA double strands are
no longer complementary to each other). To get further insight
into the methylation patterns, we studied the same 26 CpGs on
the anti-sense strand in 14 FTLD expansion carriers randomly
selected based on different methylation degree of the sense
strand: high methylated (n ¼ 4), low methylated (n ¼ 4) and
unmethylated samples (n ¼ 6). The results revealed that the pos-
ition and number of methylated CpGs was mostly concordant
between the strands (Supplementary Material, Fig. S5A).
DISCUSSION
We report the first investigation of DNA methylation at the
C9orf72 locus in an FTLD cohort. Methylation level of the
5′ CpG-island was significantly higher in FTLD expansion car-
riers than non-carriers. Methylation equally affected both the
sense and anti-sense DNA strands, suggesting that it is likely
to be a stable epigenetic modification maintained by DNA
(cytosine-5)-methyltransferase 1 rather than a transitional phe-
nomenon of active or passive demethylation (28–30). Import-
antly, the investigated CpG-island is mapped to the promoter
of C9orf72 and not any other neighboring gene on either
strand (Supplementary Material, Fig. S5B). Therefore, hyper-
methylation would likely only affect C9orf72.
The current study was limited to DNA isolated from blood,
since brain tissue was not available for our clinical cohort of
FTLD patients. However, the methylation data obtained from
blood DNA likely well-reflects the degree of methylation in
brain tissue, since in a prior ALS study we observed high con-
cordance of methylation level across different tissues (blood,
frontal cortex and cervical spinal cord) using two independent
assays (15). Moreover, while our manuscript was in preparation,
Belzil et al. (31) detected DNA hypermethylation in cerebellum
of an FTLD expansion carrier using our bisulfite sequencing
protocol.
Combined analysis of the FTLD and ALS datasets revealed
that the hypermethylation is expansion-specific, since a high
level of methylation was not observed in any of the 415 non-
carriers, irrespective of their disease status (FTLD, ALS or con-
trols) and ethnic origin (Italian or Canadian). Of note, DNA
samples from individuals with intermediate alleles (up to 43
repeats) were unmethylated, challenging the current 30-repeat
cutoff for pathological alleles.
Analysis of all 82 expansion carriers suggested that methyla-
tion level is not a major modifying factor for disease phenotype
(ALS versus FTLD). However, a tendency for more highly
methylated samples was detected in ALS (P ¼ 0.09). This obser-
vation could be important if proved to be significant in a larger
dataset. Methylation degree was known to increase with the
number of GAA-repeats in Friedreich’s ataxia (32). The trend
Table 2. Methylation level of blood DNA from FTLD expansion carriers, FTLD non-carriers and controls
Methylation level (number of methylated CpG) FTLD expansion FTLD non-expansion Control
N Frequency N Frequency N Frequency
No methylation (0) 15 0.44 159 0.96 94 0.91
Low methylation (1–3) 12 0.35 7 0.04 9 0.09
High methylation (4–26) 7 0.21 0 0 0 0
Total 34 166 103
Pa: compared with FTLD carriers 7.8E213∗ 8.3E-9∗
Pa: compared with FTLD non-carriers 0.128
aTwo-sided Pearson x2 test or Fisher’s exact test was used (when expected value ,5).
∗ P , 0.05.
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observed in our study may suggest that ALS is associated with
the higher repeat number than FTLD. Such a possibility is in
agreement with a Southern blot study of 60 expansion carriers,
which showed that despite a substantial overlap in repeat
length in peripheral blood, ALS patients had a higher repeat
number than FTLD patients (33). However, this finding requires
further validation given that an independent study did not detect
any statistical difference in repeat length between motor neuron
disease (MND; the most common form of which is ALS), FTLD
and FTLD/MND in frontal cortex (n ¼ 41), cerebellum (n ¼ 40)
or blood (n ¼ 47) (34); although, the median repeat length
appears to be higher in the blood of MND than FTLD patients.
Intriguingly, we detected a high methylation level of the
CpG-island only in 36% of expansion carriers, yet down-
regulation of C9orf72 expression seems to be more prevalent,
since it was previously reported in all evaluated expansion car-
riers (8,10,25,35–37). Reduced RNA levels (both mRNA and
pre-mRNA) were also detected in neurons differentiated from
induced pluripotent stem cells obtained from C9orf72 ALS
patients (37). It is possible that hypermethylation of another
Figure2.Methylation frequency of each CpG-site for the three investigated groups: FTLD expansion carriers, non-carriers and controls. The proportion of methylated
samples to all samples in each subgroup is presented.
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CpG-island located physically distant from but conformation-
ally close to the repeat is also involved. Moreover, it is possible
that we studied only the tail end of the methylated region, since
the G4C2-repeat forms an extra CpG-island exclusively in ex-
pansion carriers and thus could also be a target for DNA methy-
lation. However, studying the methylation of the G4C2-repeat
itself is challenging and requires the development of a novel
approach, since the expansion cannot be amplified/sequenced
by standard methods.
In addition, other epigenetic modifications such as histone
methylation could contribute to down-regulation of C9orf72.
Indeed, a recent small-scale study reported that trimethylation
of histones H3 and H4 at several lysine residues was related to
the reduced expression of C9orf72 (38). Treating fibroblasts
derived from expansion carriers with 5′-aza-2′-deoxycytydine
(a demethylating agent of both DNA and histones) increased
C9orf72 expression. Such findings indicate that both DNA and
histone methylation could be important in the regulation of
C9orf72. In epigenetic gene regulation, histone methylation pro-
vides labile transcriptional repression, whereas DNA methyla-
tion is a stable long-term silencing marker (39). Both could
trigger the other and restrict transcriptional factors from
accessing DNA as a result of heterochromatin formation (39).
In expansion carriers, reduced transcription of mRNA and
increased binding of mutant C9orf72 to trimethylated histones
was found in both patients and asymptomatic carriers (15,38),
thus the repression of C9orf72 seems to be a long-term effect
that likely involves DNA methylation. Moreover, the global
methylation pattern of DNA and histone modifications are
known to change with aging (40) and thus could be linked to
the mid-adulthood onset of disease. Further studies are needed
to determine whether the DNA and histone methylation are coor-
dinated with each other and together contribute to the disease
mechanism. However, in the current study we had access only
to DNA samples that cannot be used in a histone analysis,
which requires either cell lines or whole blood.
In conclusion, we have shown that hypermethylation of the
CpG-island 5′ of the repeat is expansion-specific in FTLD
patients, and occurred at a rate comparable to that seen in ALS
study (15). A trend towards a higher proportion of ALS patients
with a high methylation level versus FTLD may suggest that
more ALS samples are in the high range of repeat number.
Further validation of such observations may help improve
future diagnosis of C9orf72-related diseases. Also, future
studies have to include the investigation of DNA methylation
along with other epigenetic mechanisms (e.g. histone modifica-
tions); as well as large consortium studies assessing the link
between epigenetic markers and clinical parameters (e.g.
disease duration).
MATERIALS ANDMETHODS
Human samples
Informed consent was obtained from all participants in accord-
ance with the ethics review boards. DNA extracted from blood
was available for 200 unrelated FTLD patients and 103 neuro-
logically normal controls of Italian origin (.62 years old)
(Table 1). The FTLD participants, mainly of Italian origin
(except 6 from Argentina and 4 from Canada), were recruited
from hospitals specializing in neurodegenerative disorders and
diagnosed using established clinical criteria (41). To increase
the sample size and compare the methylation level between
ALS versus FTLD, we also studied blood DNA from 11 new
Canadian ALS expansion carriers (including one ALS/FTLD
patient) in addition to the reported cohort of 37 ALS expansion
carriers (15).
C9orf72 genotyping
The C9orf72 G4C2-repeat was genotyped by a two-step strategy
as previously described (27). Briefly, the first step was the fluor-
escent fragment length genotyping to obtain the number of
repeats of the small alleles (,50 repeats). The second step was
the repeat-primed PCR to determine the presence of the expan-
sion (.50 repeats). Pathological expansions were defined
using the previously suggested 30-repeat cutoff (8,9).
Bisulfite sequencing
As described previously (15), each DNA sample was sequenced
following bisulfite conversion, after which unmethylated C are
read as T, while methylated C remain unchanged. The methyla-
tion status of each CpG was classified as unmethylated (T peak)
or methylated (T/C double peaks). Only samples with .95%
conversion rates of non-CpG C were included in the analyses.
For each sample, we obtained the total number of methylated
CpGs. All primers and experimental conditions for genotyping
or methylation analyses are available in previous reports
(15,27). For bisulfite sequencing of the anti-sense DNA strand
(non-coding for C9orf72), the same CpG-island was amplified
by a semi-nested PCR (in two tandem amplicons) and sequenced
(Supplementary Material, Table S3). To validate the results of
direct bisulfite sequencing, PCR products were cloned (TOPO
TA cloning kit, Invitrogen) and sequenced in both directions
using commercial vector primers (M13 Forward and M13
Reverse). For each sample, 10 clones were sequenced and the
methylation percentage was calculated as follows: (the overall
methylated CpG sites/the total studied CpG sites) × 100%.
Methylation sensitive restriction enzyme assay
As described previously (15), each DNA sample was amplified
after incubation with or without HhaI. The PCR product from
the digested and undigested DNA was resolved on a 1.5%
agarose gel and quantified using black/white inverted gel
images to obtain the OM ratio.
Statistical analyses
A linear regression analysis was performed between the OM ratio
(HhaI-assay) and number of methylated CpG sites (bisulfite
sequencing assay) to assess the correlation between the two
assays. Spearman’s correlation coefficients were used to
measure the correlation between independent variables: repeat
size (,50 repeats), age, disease duration and methylation level.
The independent samples t-test or the non-parametric Mann–
Whitney U test was used to compare continuous variables
between two groups as appropriate. The two-sided Pearson
x2 test or Fisher’s exact test (when expected value ,5) was
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used to compare categorical variables. All analyses were per-
formed using SPSS (version 20).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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